First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Ozaras, Resat
Senates, Ebubekir
Tabak, Fehmi
Cagatay, Atahan
Mete, Bilgul
Ceylan, Bahadir
Ozgunes, Nail
Gunduz, Alper
Karaosmanoglu, Hayat
Gokturk, Kadir
Erdem, Levent
Kocak, Funda

Open link

Publication date

January 2014

DOI

10.1097/meg.0000000000000099

Publisher

Ovid Technologies (Wolters Kluwer Health)

Journal

European Journal of Gastroenterology & Hepatology

Abstract

Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance

Extracted data

We use cookies to provide a better user experience.

Data Protection

First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Abstract

Extracted data

First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Abstract

Extracted data

Related items

Related items